Rareboost External Seminar Announcement – Prof. Dr. Ahmet Özen

We are pleased to announce an upcoming seminar featuring Prof. Dr. Ahmet Özen, a leading expert in the field of Pediatric Allergy and Immunology. Titled as “Decoding CHAPLE Disease: Accelerating from Genomic Discovery to Precision Therapeutics”, the seminar will unravel the journey of CHAPLE Disease.

The seminar will be held on 12 January 2024 at 11:00 in İzmir Biomedicine and Genome Center, Aziz Sancar Auditorium.

Clicke here to watch the seminar online via Zoom. Meeting ID: 972 5260 7452 Password: 344318

Introducing Prof. Dr. Ahmet Özen

Dr. Ahmet Özen is a leading expert in the field of Pediatric Allergy and Immunology, currently serving as the Division Chief of the Pediatric Allergy and Immunology Program at Marmara University and director at the Istanbul Jeffrey Modell Foundation Center. Dr. Özen earned his medical degree at Marmara University, where he also specialized in Pediatrics. Following this, Dr. Özen completed a residency in Allergy and Immunology at Yeditepe University. To further enhance his expertise, Dr. Özen pursued a postdoctoral fellowship at the Laboratory of Immunology, NIAID, at the National Institutes of Health (NIH). Dr. Özen is globally recognized for his groundbreaking contributions to genetic and immunological research. His research on CD55 deficiency in CHAPLE disease played a pivotal role in the FDA’s endorsement of pozelimab. His group has also identified numerous gene mutations in immune dysregulation diseases which cause intestinal inflammation. Dr. Özen is a dedicated mentor, nurturing the next generation of researchers with a mission to advance immunological research and translational medicine.

Decoding CHAPLE Disease: Accelerating from Genomic Discovery to Precision Therapeutics

CHAPLE disease is a rare genetic condition that affects the immune system, leading to severe gastrointestinal problems. In this talk,I’ll explore the transformative journey of CHAPLE disease from genetic revelation to therapeutic breakthrough. The identification of CD55 mutations illuminated the connection between complement dysregulation and gastrointestinal pathology, expediting therapeutic development. The FDA’s rapid approval of pozelimab, underscores the swift advancements in this area. My role in translating these genetic insights into clinical practice has redefinedCHAPLE disease treatment, showcasing the power of precision medicine. Thispresentation will address the challenges in rare disease management, the impact on affected families, and the role of genomic medicine in identifying new treatment pathways. CHAPLE disease exemplifies the potential of genomics research to reveal unforeseen mechanisms and therapeutic possibilities across a spectrum of disorders.